

Mi Kwon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4241892/publications.pdf>

Version: 2024-02-01

60
papers

1,020
citations

567247

15
h-index

477281

29
g-index

62
all docs

62
docs citations

62
times ranked

1752
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 and stem cell transplantation; results from an EBMT and CETH multicenter prospective survey. <i>Leukemia</i> , 2021, 35, 2885-2894.	7.2	153
2	Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. <i>Cancer Medicine</i> , 2021, 10, 3214-3223.	2.8	73
3	Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. <i>Leukemia</i> , 2021, 35, 3585-3588.	7.2	72
4	Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. <i>Infection</i> , 2021, 49, 215-231.	4.7	63
5	Mechanisms That Contribute to a Profound Reduction of the HIV-1 Reservoir After Allogeneic Stem Cell Transplant. <i>Annals of Internal Medicine</i> , 2018, 169, 674.	3.9	59
6	Evaluation of Minimal Residual Disease by Real-Time Quantitative PCR of Wilms Tumor 1 Expression in Patients with Acute Myelogenous Leukemia after Allogeneic Stem Cell Transplantation: Correlation with Flow Cytometry and Chimerism. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1235-1242.	2.0	57
7	Haplo-Cord Transplantation Using CD34+ Cells from a Third-Party Donor to Speed Engraftment in High-Risk Patients with Hematologic Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2015-2022.	2.0	42
8	A Case-Control Study of Real-Life Experience with Ceftolozane-Tazobactam in Patients with Hematologic Malignancy and Pseudomonas aeruginosa Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	34
9	Single Cord Blood Combined with HLA-Mismatched Third Party Donor Cells: Comparable Results to Matched Unrelated Donor Transplantation in High-Risk Patients with Hematologic Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 143-149.	2.0	28
10	Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial. <i>Lancet Haematology</i> , 2022, 9, e14-e25.	4.6	27
11	A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms. <i>Blood Advances</i> , 2018, 2, 1719-1737.	5.2	25
12	Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation. <i>Blood Advances</i> , 2019, 3, 3351-3359.	5.2	25
13	Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation. <i>Annals of Hematology</i> , 2021, 100, 541-553.	1.8	25
14	Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms. <i>Cancers</i> , 2019, 11, 1364.	3.7	23
15	Short Tandem Repeats (STRs) as Biomarkers for the Quantitative Follow-Up of Chimerism after Stem Cell Transplantation: Methodological Considerations and Clinical Application. <i>Genes</i> , 2020, 11, 993.	2.4	19
16	Retrospective Multicenter Study of Extracorporeal Photopheresis in Steroid-Refractory Acute and Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 651-658.	2.0	18
17	Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	17
18	Graft-Versus-Tumor Effect After Allogeneic Stem Cell Transplantation in HIV-Positive Patients With High-Risk Hematologic Malignancies. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1340-1345.	1.1	16

#	ARTICLE	IF	CITATIONS
19	Inhibitory killer cell immunoglobulin-like receptor (<sc>iKIR</sc>) mismatches improve survival after T-cell-repleted haploidentical transplantation. <i>European Journal of Haematology</i> , 2016, 96, 483-491.	2.2	15
20	Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide. <i>Hematological Oncology</i> , 2020, 38, 597-603.	1.7	14
21	Polyphasic characterization of fungal isolates from a published case of invasive aspergillosis reveals misidentification of <i>Aspergillus felis</i> as <i>Aspergillus viridinutans</i> . <i>Journal of Medical Microbiology</i> , 2014, 63, 617-619.	1.8	13
22	Factors predicting peripheral blood progenitor cell mobilization in healthy donors in the era of related alternative donors: Experience from a single center. <i>Journal of Clinical Apheresis</i> , 2019, 34, 373-380.	1.3	13
23	Allogeneic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disorders. <i>Aids</i> , 2019, 33, 1441-1447.	2.2	13
24	Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, e05209.	0.5	13
25	Antithymocyte Globulin-Based Prophylaxis for Graft Versus Host Disease Compared to Post-Transplant Cyclophosphamide-Based Prophylaxis in Matched Unrelated Donor Transplantation. <i>Blood</i> , 2016, 128, 2307-2307.	1.4	12
26	The Genotype of the Donor for the (GT) _n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation. <i>PLoS ONE</i> , 2015, 10, e0140454.	2.5	11
27	Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2018, 101, 332-339.	2.2	11
28	Evolution of the role of haploidentical stem cell transplantation: past, present, and future. <i>Expert Review of Hematology</i> , 2020, 13, 835-850.	2.2	11
29	Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience From the Madrid Group of Hematopoietic Transplant. <i>Frontiers in Immunology</i> , 2021, 12, 674658.	4.8	10
30	Clinical Utility of the Detection of the Loss of the Mismatched HLA in Relapsed Hematological Patients After Haploidentical Stem Cell Transplantation With High-Dose Cyclophosphamide. <i>Frontiers in Immunology</i> , 2021, 12, 642087.	4.8	9
31	Transjugular Intrahepatic Portosystemic Shunt for Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-transplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2089-2097.	2.0	8
32	Implementation of a hospital-at-home (HAH) unit for hematological patients during the COVID-19 pandemic: safety and feasibility. <i>International Journal of Hematology</i> , 2022, 115, 61-68.	1.6	8
33	Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia. <i>Blood Advances</i> , 2017, 1, 1047-1055.	5.2	6
34	Mononuclear cell collection for extracorporeal photopheresis by using the <i>off-line</i> system: A comparative study between COBE Spectra and Spectra Optia devices. <i>Journal of Clinical Apheresis</i> , 2019, 34, 359-366.	1.3	6
35	Tocilizumab as salvage treatment of refractory pulmonary acute graft-versus-host disease. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 751-755.	0.9	6
36	Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TC. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 204.e1-204.e10.	1.2	6

#	ARTICLE	IF	CITATIONS
37	Recomendaciones de GESIDA/PETHEMA sobre el diagnóstico y tratamiento de los linfomas en pacientes infectados por el virus de la inmunodeficiencia humana. Medicina Clínica, 2018, 151, 39.e1-39.e17.	0.6	5
38	Clinical utility of targeted next-generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition. Molecular Oncology, 2021, 15, 2273-2284.	4.6	5
39	Achievement of early complete donor chimerism in CD25+ activated leukocytes is a strong predictor of the development of graft-versus-host-disease after stem cell transplantation. Experimental Hematology, 2015, 43, 4-13.e1.	0.4	4
40	Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma. Blood, 2020, 136, 19-21.	1.4	4
41	Infectious Complications and Mortality after Autologous Stem Cell Transplantation for Lymphomas: A Comparison Between HIV-Infected and HIV-Negative Patients. Blood, 2016, 128, 2258-2258.	1.4	4
42	A New Multiple Single-Nucleotide Polymorphisms Based Predictive Model for Grades III to IV and Extensive Graft Versus Host Disease after Identical HLA-Allogeneic Stem-Cell. Blood, 2015, 126, 921-921.	1.4	4
43	Transient hemolysis due to anti-CD and anti-CA 1 produced by engrafted donor's lymphocytes after allogeneic unmanipulated haploidentical hematopoietic stem cell transplantation. Transfusion, 2017, 57, 2355-2358.	1.6	3
44	Assessing the impact on intestinal microbiome and clinical outcomes of antibiotherapy optimisation strategies in haematopoietic stem cell transplant recipients: study protocol for the prospective multicentre OptimBioma study. BMJ Open, 2020, 10, e034570.	1.9	3
45	COVID-19 and Stem Cell Transplantation; Results from the Prospective Survey By the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH). Blood, 2020, 136, 32-33.	1.4	3
46	Immune Reconstitution Impact on Overall Survival after Hematopoietic Haploidentical Stem Cell Transplantation. Blood, 2016, 128, 5779-5779.	1.4	3
47	Risk prediction of CMV reactivation after allogeneic stem cell transplantation using five non-HLA immunogenetic polymorphisms. Annals of Hematology, 2022, 101, 1567-1576.	1.8	3
48	Successful Treatment of Severe Aspergillosis with Isavuconazole Therapy after Allogeneic Stem Cell Transplantation. Chemotherapy, 2019, 64, 57-61.	1.6	2
49	Autologous stem cell transplantation for lymphoma in HIV+ patients: higher rate of infections compared with non-HIV lymphoma. Bone Marrow Transplantation, 2020, 55, 1716-1725.	2.4	2
50	Next Generation Cytogenetics in Myeloid Hematological Neoplasms: Detection of CNVs and Translocations. Cancers, 2021, 13, 3001.	3.7	2
51	Cytokine Release Syndrome after Allogeneic Stem Cell Transplantation with Post Transplant Cyclophosphamide. Blood, 2018, 132, 3367-3367.	1.4	2
52	Myeloablative Conditioning Haploidentical Stem Cell Transplantation (MAC-HAPLO) with Post-Transplant Cyclophosphamide (PTCy) As GvHD Prophylaxis in High Risk Leukemias/Myelodysplastic Syndromes (MDS): Geth Experience. Blood, 2016, 128, 4690-4690.	1.4	2
53	Clinical grade production of IL-15 stimulated NK cells for early infusion in adult AML patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide. Transfusion, 2022, 62, 374-385.	1.6	2
54	Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Transplantation Compared to ATG-Based Prophylaxis. Blood, 2019, 134, 3285-3285.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Very Severe Veno-Occlusive Disease after Unmanipulated Haploidentical HSCT with Post-Transplant Cyclophosphamide. <i>Blood</i> , 2019, 134, 1981-1981.	1.4	1
56	Donor and Recipient Genotypes for Interleukin 1 Gene Single Nucleotide Polymorphisms (SNPs) Allow Anticipation of Acute Graft Versus Host Disease after HLA-Identical Allogeneic Stem Cell Transplantation (allo-SCT). <i>Blood</i> , 2014, 124, 666-666.	1.4	1
57	Genetic biomarkers identify a subgroup of high-risk patients within low-risk NPM1-mutated acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1178-1186.	1.3	1
58	Axicabtagene Ciloleucel Compared to Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma in the Real World Setting in Spain. <i>Blood</i> , 2021, 138, 1742-1742.	1.4	1
59	Impact of Minimal Residual Disease and Chimerism Monitoring at Different Timepoints after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 7-7.	1.4	1
60	Influence of CD34+ and CD3+ Graft Content on Gvhd Development after Haploidentical Allogeneic Transplantation with Post-Transplant Cyclophosphamide. <i>Blood</i> , 2015, 126, 3131-3131.	1.4	0